This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use | MicrobiomeTrials
← Back to trials NCT03145857
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use TERMINATED PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2020-03-05Est. Completion: 2026-08-24
Enrollment target: 634 participantsLocations Cross Cancer Institute, Edmonton, Alberta, Canada Other microbiome trials you might be interested in Melanoma
Background:
The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the dige…
Loma Linda, United States Completed Oct 31, 2027
Neuroendocrine Tumors Carcinoid Tumor
Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from t…
Aarau, Switzerland Completed Aug 31, 2025
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HC…
Philadelphia, United States Est. completion Nov 13, 2026